Background. The accumulation of larger and proteinbound toxins is involved in the uraemic syndrome but their elimination by dialysis therapy remains difficult. In the present study, the impact of the albumin permeability of recently introduced advanced high-flux dialysis membranes C The
on the removal of such substances was tested in haemodialysis and online post-dilution haemodiafiltration. Methods. Two types of polyethersulfone membranes only differing in albumin permeability (referred as PU− and PU+) were compared in eight patients on maintenance dialysis in a prospective cross-over manner. Treatment settings were identical for individual patients: time 229 ± 22 min; blood flow rate 378 ± 33 mL/min; dialysate flow rate 500 mL/min; substitution flow rate in haemodiafiltration 94 ± 9 mL/min. Removal of the protein-bound compounds p-cresyl sulfate (pCS) and indoxyl sulfate (IS) was determined by reduction ratios (RRs), dialytic clearances and mass in continuously collected dialysate. In addition, the elimination of the low-molecular weight (LMW) proteins beta 2 -microglobulin, cystatin c, myoglobin (myo), free retinol-binding protein (rbp) and albumin was measured.
Results. Plasma levels of the protein-bound toxins were significantly decreased by all treatment forms. However, the decreases were comparable between dialysis membranes and between haemodialysis and haemodiafiltration. The RRs of total pCS ranged between 40.4 ± 25.3 and 47.8 ± 10.3% and of total IS between 50.4 ± 2.6 and 54.6 ± 8.7%. Elimination of free protein-bound toxins as assessed by their mass in dialysate closely correlated positively with the pre-treatment plasma concentrations being r = 0.920 (P < 0.001) for total pCS and r = 0.906 (P < 0.001) for total IS, respectively. Compared to haemodialysis, much higher removal of all LMW proteins was found in haemodiafiltration. Dialysis membrane differences were only obvious in haemodialysis for the larger LMW proteins myo and rbp yielding significantly higher RRs for PU+ (myo 46 ± 9 versus 37 ± 9%; rbp 18 ± 5 versus 15 ± 5%; P < 0.05). Additionally, the albumin loss varied between membranes and treatment modes being undetectable with PU− in haemodialysis and highest with PU+ in haemodiafiltration (1430 ± 566 mg).
Conclusions. The elimination of protein-bound compounds into dialysate is predicted by the level of pre-treatment plasma concentrations and depends particularly on diffusion. Lacking enhanced removal in online post-dilution haemodiafiltration emphasizes the minor significance of convection for the clearance of these solutes. Compared to LMW proteins, the highly protein-bound toxins pCS and IS are less effectively eliminated with all treatment forms. For a sustained decrease of pCS and IS plasma levels, alternative strategies promise to be more efficient therapy forms.
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Introduction
A large number of retained compounds are involved in uraemic toxicity. Among them are larger solutes and protein-bound compounds, which seem to be related to deleterious biological and clinical effects but are difficult to remove by dialysis [1] . Particularly, protein-bound toxins represent a challenge for extracorporeal renal replacement strategies because only the unbound, mostly low-molecular solute can pass current dialysis membranes while the bound fraction is retained. P-cresol is one of the most frequently studied proteinbound toxins in end-stage renal disease to date. The free pcresol serum concentration is significantly associated with cardiovascular disease in non-diabetics on haemodialysis and is suited to predict overall mortality in this patient group [2, 3] . The interrelation of p-cresyl sulfate (pCS), the main in vivo metabolite of p-cresol, with vascular disease in uraemia may be derived from its pro-inflammatory effect on unstimulated leucocytes leading to oxidative stress and, consequently, atherosclerosis [4] .
Similar to other protein-bound compounds, pCS is poorly removed by haemodialysis because of its protein binding and its high ratio of distribution volume to clearance [5] . Compared with low-flux, high-flux dialysis membranes generally do not enhance the elimination of protein-bound toxins, while albumin-leaking super-flux membranes are superior especially in removing indoxyl sulfate (IS) [6, 7] . Convection seems to positively impact protein-bound toxin removal because haemodiafiltration is able to increase pcresol clearance without leading to excessive albumin loss [8] .
Recently, advanced synthetic high-flux dialysis membranes were introduced for extracorporeal renal replacement therapy. These membranes are characterized by optimized, i.e. steeper sieving profiles with an improved selective permeability for low-molecular weight (LMW) proteins and an efficiency in conventional haemodialysis similar to online haemodiafiltration with standard highflux membranes [9, 10] . In the present study, two such types of high-performing dialysis membranes only differing in albumin permeability were compared in haemodialysis and online high-efficiency post-dilution haemodiafiltration regarding the removal of protein-bound toxins and LMW proteins.
Patients and methods

Study design
Study approval was given by the local ethics committee, and the competent authorities were notified (registration no. 0007565). The study design was prospective, randomized and cross-over.
Eight stable chronic kidney disease stage 5 patients on regular three times weekly maintenance dialysis were enrolled into the study after they had given written informed consent. The patient's concomitant medications were continued in an unchanged manner.
Each patient underwent randomly one study week of three consecutive haemodialysis treatments with the PUREMA R H dialysis membrane (referred as PU−; synthetic, high-flux polyethersulfone, 1.9 m 2 , γ-sterilized; Xenium 190 dialyser, Baxter Healthcare, McGaw Park, IL, USA) and one week with the PUREMA R H+ dialysis membrane (referred as PU+; 1.9 m 2 ; Pureflux R 190 H+ dialyser, Nipro Corp., Osaka, Japan). The K O A for urea of PU− and PU+ measured in vitro in aqueous conditions at a blood flow rate (Q B ) of 300 mL/min and dialysate flow rate (Q D ) of 800 mL/min were 1598 ± 140 and 1667 ± 165 mL/min, respectively. The two dialysis membranes only differed in the sieving coefficient for albumin being 0.002 for PU− and 0.003 for PU+. After the haemodialysis period, the patients were randomly subjected to one week of three consecutive online post-dilution haemodiafiltration treatments with each of the dialysis membranes.
Haemodialysis and haemodiafiltration were performed using Fresenius 4008 H monitors (Fresenius Medical Care, Bad Homburg, Germany). Treatment duration, Q B and Q D , as well as the infusion flow rate (Q I ) in post-dilution haemodiafiltration were kept constant for each patient. The ultrafiltration flow rate (Q UF ) of each session was set according to the individual patient's interdialytic weight gain. Anticoagulation was performed by unchanged adoption of the previous routine heparinization.
Quantitation of treatment efficacy
Treatment efficacy was determined during the third (mid-week) consecutive session of each respective period by measuring instantaneous plasma clearances (K), dialytic clearances and reduction ratios (RRs). The total mass (M TD ) of protein-bound toxins and albumin was detected in continuously collected dialysate.
K was measured after 30 min and 180 min of the treatment for the small solutes urea (60 Da) and phosphate (PO 4 ; 96 Da) and for the LMW proteins beta 2 -microglobulin (b2m; 11,800 Da), cystatin C (cysc; 13 400 Da), myoglobin (myo; 17 800 Da), and free retinol-binding protein (rbp; 21.200 Da). Plasma concentrations were determined in blood samples obtained from the arterial (C art ) and the venous (C ven ) blood line of the extracorporeal circuit. During sampling, Q UF was maintained. Q UF was taken into account for calculation of K [11] . Plasma water clearances were obtained by calculation according to equation 1 using the patient's haematocrit level (Hct) at the time of the respective clearance sampling and the pre-dialysis total protein level (TP, g/L) [12] . To account for solute shift from the blood cell, solute partition coefficients (SPC) were assumed as 0.86 (urea), 0.5 (phosphate) and 0 (LMW proteins), respectively [12] .
RRs were determined for the LMW proteins b2m, cysc, myo and rbp, and the protein-bound substances for pCS, p-cresyl glucuronide (pGC) and IS. Plasma concentrations were measured in blood samples drawn from the arterial blood line before (C pre ) and at the end (C post ) of each treatment after reduction of Q B to 50 mL/min for 30 s, and Q D was turned off. RR was calculated according to equation 2 using corrected C post (C post-corr ) [13] . C post was corrected for extracellular volume changes based on differences in the patient's pre-(BW pre ) and post-dialysis body weight (BW post ) (equation 3) [14] .
M TD was determined by continuously collecting a spent dialysate fraction of 10 mL/min during the whole dialysis duration (t) via a T-connector inserted into the dialysate drainage line. The concentrations (C D ) of pCS, IS and albumin were determined in an aliquot taken from the collected spent dialysate. M TD was calculated according to equation 4.
Obtaining reliable clearances for protein-bound solutes from simultaneous arterial and venous concentrations is very difficult because of only small differences across the dialyser [5] . Therefore, despite producing rather a rough estimate, dialytic clearances of the protein-bound toxins were calculated by dividing M TD by the log mean of the pre-and posttreatment plasma levels and the treatment duration [8] .
Based on the distribution volume of pCS, which is about 205 mL/kg body weight and much larger than the plasma volume [5] , the mass transfer rate and the mass balance error were estimated for the protein-bound toxins pCS and IS as an equivalent for adsorption onto the dialysis membranes. The whole body mass of protein-bound solutes was calculated by multiplying the plasma concentration with the total volume of distribution. The mass transfer rate was derived from the difference between whole body mass before and after treatment. The mass balance error was calculated as the difference between the mass transfer rate and the mass recovered in dialysate.
Analytical methods
The total and unbound (free) portions of the protein-bound substances pCS and IS were determined by high-performance liquid chromatography (HPLC) according to Meert et al. [15] . Blood samples were collected in tubes containing 1 mg tetrahydrolipstatin to avoid the activation of the lipoprotein lipase in plasma by heparin and the generation of free fatty acids that would compete with the protein-bound solutes for their binding sites. Different to methods described earlier [6] , deproteinization of the plasma samples was performed with heat (95 • C for 30 min) instead of acidification to avoid hydrolysis of the p-cresol conjugates allowing the detection of conjugated pCS.
As standards, pCS was kindly provided by Prof. Raymond Vanholder, University of Ghent, Belgium, while IS was purchased from Sigma, Taufkirchen, Germany. The standards were further purified by reversed phase HPLC. They equalled coeluting peaks derived from plasma of uraemic individuals by mass spectroscopy [HCT IonTrap LC/MS-system (Bruker Daltronic GmbH, Bremen, Germany)].
Small
Data analysis
Descriptive analysis of the results was performed by calculating mean values ± standard deviations (SD). After testing for normal distribution of the samples, within-subject between-treatment differences were analysed by ANOVA and a Tukey post hoc test. Comparative statistical analyses of within-subject within-treatment changes from baseline were assessed using the two-sided paired t-test. Correlation coefficients were determined for pre-treatment plasma concentrations and M TD of protein-bound compounds according to Pearson. A P-value of <0.05 was considered statistically significant. The statistical analysis was performed by means of the 'Minitab Release 4' statistical software package (Minitab, Inc., State College, PA, USA).
Results
Patient data
One female and seven male patients had a mean age of 63 ± 12 years. Underlying renal diseases were cast nephropathy (n = 2), diabetic nephropathy (n = 1), glomerulonephritis (n = 1), hypertensive nephropathy (n = 1), primary amyloidosis (n = 1), Alport syndrome (n = 1) and unknown (n = 1). The mean duration on dialysis treatment was 81.8 ± 144.0 months (range 3-411 months). The mean postdialysis body weight was 70.8 ± 18.6 kg. All patients were anuric. Four patients had efficient native arteriovenous fistulas and four patients had patent bi-flow dialysis catheters for blood access.
Treatment data
The treatment duration was 229 ± 22 min. Q B and Q D averaged at 378 ± 33 mL/min and 500 ± 0 mL/min, respectively. Q I in post-dilution haemodiafiltration was 94 ± 9 mL/min. Q UF was not different for the four treatment periods (PU− in HD 2673 ± 510 mL; PU+ in HD 2726 ± 816 mL; PU− in HDF 3013 ± 651 mL; PU+ in HDF 2838 ± 1208 mL). Six patients received standard heparin, one patient fractionated heparin and another patient did not receive any heparin due to severe thrombopenia associated with lupus erythematodes.
Laboratory data
The relative binding of protein-bound toxins was not different before and after treatment being 96.0 ± 2.4 and 96.3 ± 3.1% for pCS and 95.0 ± 4.6 and 94.9 ± 3.7% for IS. Except for the free portion of pCS, which was not significantly decreased by all treatment modes, haemodialysis 8.3 ± 6.1 * * 85 ± 57 Free 0.9 ± 1.0 0.4 ± 0.4 * 86 ± 80 0.6 ± 0.4 0.3 ± 0.2 * * 85 ± 57 * P < 0.05 versus pre-treatment concentration. * * P < 0.01 versus pre-treatment concentration. # P < 0.001 versus pre-treatment concentration. Since bound toxins cannot pass the dialysis membrane, the free and bound portion in dialysate are equal. Results of haemodialysis and online postdilution haemodiafiltration with the PU− and the more permeable PU+ dialysis membrane are given. No differences were found between PU− and PU+ in the same treatment mode and between haemodialysis and haemodiafiltration. Results of haemodialysis and online post-dilution haemodiafiltration with the PU− and the more permeable PU+ dialysis membrane are given. No differences were found between PU− and PU+ in the same treatment mode and between haemodialysis and haemodiafiltration.
and haemodiafiltration with both PU− and PU+ led to a significant reduction of the plasma concentrations of free and total IS and total pCS ( Table 1 ). The RRs for total pCS (between 40.4 ± 25.3% in PU+ HDF and 47.8 ± 10.3% in PU− HDF) and total IS (between 50.4 ± 2.6% in PU− HD and 54.6 ± 8.7% in PU− HDF) were all on a similar level ( Table 2 ). There was no significant difference between any of the four treatment forms regarding pre-treatment plasma concentrations, RRs and M TD of protein-bound toxins. Compared with the total fraction, the dialytic clearances of the free fractions of pCS and IS were considerably higher ( Table 2 ). No significant difference between treatment modes was noted.
The mass balance error for total pCS (between 43 ± 44 and 81 ± 62 mg) and total IS (between 51 ± 52 and 60 ± 41 mg) was not different between dialysis membranes (Table 2 ). Even after the dialysis forms were combined irrespective of the type of membrane, no difference between haemodialysis and haemodiafiltration was determined (Table 2) .
While a significant effect of any treatment form on the removal of the protein-bound compounds was absent, the M TD as one measure for solute elimination closely correlated positively with the pre-treatment plasma concentrations. For the total and free portions, this linear relationship was r = 0.906 and r = 0.800 for IS (P < 0.001) and r = 0.920 and r = 0.873 for pCS (P < 0.001), respectively.
The instantaneous plasma clearances of PU− and PU+ for urea at 30 min and PO 4 at 30 and 180 min were significantly lower in haemodialysis compared with haemodiafiltration (Table 3) . For all LMW proteins, K was lower (P < 0.001) in haemodialysis than in haemodiafiltration without differences between the two dialysis membranes (Table 3) . Similarly, the LMW protein RRs were throughout lower (P < 0.001) in haemodialysis mode (Table 4) . Compared to PU+, the RRs obtained in haemodialysis with PU− were lower for the larger LMW proteins myo and rbp (Table 4) . For the smaller middle molecules b2m and cysc, the RRs were almost identical in haemodialysis with both dialysis membranes.
Significant differences were found between the dialysis membranes with respect to the albumin loss into dialysate during haemodialysis and haemodiafiltration. In haemodialysis with PU−, the albumin loss was always Table 4 . Reduction ratios of low-molecular weight proteins corrected for weight loss of haemodialysis and online post-dilution haemodiafiltration with the PU− and the more permeable PU+ dialysis membrane Reduction ratios [%] b2m cysc myo rbp PU− HD 68 ± 6 * 68 ± 6 * 37 ± 9 * * 15 ± 5 * * PU+ HD 68 ± 6 * 67 ± 6 * 46 ± 9 * 18 ± 5 * PU− HDF 78 ± 5 7 7± 5 6 5± 6 1 9± 8 PU+ HDF 78 ± 6 7 6± 5 6 6± 7 2 6± 16 * P < 0.001 versus PU− HDF and PU+ HDF. * * P < 0.05 versus PU+ HD and P < 0.001 versus PU− HDF and PU+ HDF. b2m, beta 2 -microglobulin (molecular weight 11 800 Da); cysc, cystatin c (13 400 Da); myo, myoglobin (17 600 Da); rbp, retinol-binding protein (21 200 Da) below the detection limit of 200 mg, while with PU+, it averaged at 482 ± 154 mg per treatment. In haemodiafiltration, an albumin loss of 809 ± 206 and 1430 ± 566 mg was determined with PU− and PU+, respectively ( Figure 1) .
Discussion
This small-scale study was performed to compare the impact of two differently permeable innovative dialysis membranes applied in haemodialysis and post-dilution haemodiafiltration on the removal of protein-bound toxins and LMW proteins. Both haemodialysis and haemodiafiltration decreased the plasma concentrations of all substances significantly during a single treatment. Despite the fact that the infusion volume met the criteria for high efficiency haemodiafiltration and in contrast to the effect on LMW proteins, no differences in the removal of the protein-bound toxins was found neither between treatment modes nor between the two different dialysis membranes.
This finding is inconsistent with the results from a previous trial, which reported slightly superior total p-cresol removal by highly convective renal replacement therapy including post-dilution haemodiafiltration [8] . This discrepancy may be explained by several factors: (1) the effect of convection on protein-bound toxin removal is poor compared with diffusion. Although the transferability of data from recent in vitro studies on continuous venovenous haemofiltration and haemodiafiltration to our results is difficult, they suggest that an increase of protein-bound toxin removal by higher ultrafiltration rates (i.e. convection) is little effective [16] . Alterations of the dialysate flow rate and a larger dialysis membrane surface area are more important measures to enhance protein-bound toxin elimination [17] . In this respect, it must be noted that no difference in the removal of most protein-bound toxins, including p-cresol and IS, was found between low-and highflux dialysis [6] . In contrast to high-flux dialysis, in which convection plays a considerable role, low-flux dialysis is a purely diffusive therapy form; (2) less efficacy differences between haemodialysis and haemodiafiltration, particularly with regard to convection. The dialysis membranes tested in our study represent recently introduced advanced high-flux membranes. With regard to LMW protein removal, even the less permeable PU− membrane has proven to be superior in haemodialysis compared to the Helixone R membrane used in the referenced trial [8, 9] . This difference was attributed to enhanced internal filtration, i.e. more convection, allowing the elimination of a larger quantity within a wider range of LMW proteins [9] . Accordingly, our results for dialytic clearances and mass in dialysate of pCS were rather high already in haemodialysis; (3) differences in the measurement of p-cresol. Bammens et al. applied gas chromatographic mass spectrometry for the determination of total p-cresol [8] . We used an HPLC method to differentiate the p-cresol conjugate pCS. pGC, the quantitatively less important conjugate accounting for total p-cresol, may behave completely different from pCS if its protein binding is different. The strength of binding is of particular importance for the dialytic elimination of protein-bound substances. The higher the degree of the protein binding the more difficult is the removal of a substance by dialysis therapy. Therefore, total p-cresol, i.e. pCS and pGC, may have slightly different kinetics during dialysis as pCS alone.
The two dialysis membranes under investigation only differed in albumin permeability but only marginally to avoid potential hazards of excessive albumin loss in haemodiafiltration. Although significant differences in albumin loss per session were detected between PU− and PU+ in haemodialysis and haemodiafiltration, the maximum loss, which was observed with PU+ in haemodiafiltration, averaged at only about 1.4 g. Such a value is regarded as to be by far within accepted ranges and is much lower compared with albumin-leaking super-flux dialysers used in haemodialysis mode [18, 7] . Compared with low-flux dialysis, removal of protein-bound toxins, especially IS, by super-flux dialysis is superior and is not only attributed to compounds bound to albumin passing or adsorbing to the membrane [7] . With respect to albumin loss and convection, the differences between low-and super-flux dialysers are much larger than those between PU− and PU+ in either haemodialysis or haemodiafiltration. The performance characteristics of PU− and PU+ were very similar and differences in haemodialysis were not observed for solutes smaller than myoglobin, a molecule of 17 600 Da. In haemodiafiltration, the differences in LMW protein removal between the membranes disappeared and averaged on very high levels comparable to those reported in previous trials [9, 10] . Therefore, it is conclusive to find similar pCS and also IS removal with both types of the innovative PUREMA R high-flux membrane.
According to Fick's law, the solute flux in haemodialysis is proportional to the concentration difference between plasma water and dialysate, provided that the distance and area of the diffusion front, i.e. the dialysis membrane, as well as the diffusivity, which is a property of a specific solute, are constant [19] . The M TD is essentially the resultant of solute flux. For small solutes, such as unbound pCS and IS, the concentration gradient is the driving force for diffusion [19] . The free and bound compounds in plasma are equilibrated. Depending on the solute protein binding coefficient, unbinding of solute occurs as free solute is removed [20] , as also indicated by constant relative binding despite decreased concentrations from pre-to posttreatment. In this study, M TD must be regarded as a particularly sensitive parameter for the removal of pCS and IS because the tested dialysis membranes were almost identical and, therefore, adsorption and other physicochemical differences between the membranes can be neglected. Accordingly, the mass balance errors for total pCS and IS as a measure of adsorption was not different between dialysis membranes and also treatment modes despite considerable amounts were estimated. We further analysed the data by correlating the pooled M TD and pre-treatment plasma concentrations of protein-bound compounds. Interestingly, an extremely close correlation was found for all free and total protein-bound toxins suggesting that the removal of protein-bound solutes is predicted by the pretreatment plasma concentration. The pre-treatment plasma concentration in steady state at a constant generation rate is determined by the intra-and extracorporeal clearance. Since no difference in protein-bound solute removal between treatment forms was found, the impact of convection must be of minor significance. In fact, it must be governed primarily by diffusion. This conclusion is in accordance with the findings from a previous in vitro trial studying the effects of ultrafiltration and dialysate flow in continuous haemofiltration and haemodiafiltration [16] . Moreover, the close correlations of M TD and pre-treatment plasma concentrations underline the validity of our measurements.
Conclusions
The elimination of protein-bound compounds into dialysate is governed particularly by diffusion and is predicted by the level of pre-treatment plasma concentration. RRs for free and total pCS and IS, which are involved in oxidative stress, endothelial dysfunction and potentially cardiovascular disease [4, [21] [22] [23] [24] [25] , hardly reached 50% in both haemodialysis and online post-dilution haemodiafiltration. Although our knowledge about kinetics and distribution of these compounds is limited, such values must be regarded as inadequate. For a sustained decrease of pCS and IS plasma levels, alternative strategies promise to be more efficient therapy forms. These could comprise adsorptive measures, either applied orally [25, 26] or during extracorporeal therapy [27, 28] , which interact with protein-bound compounds or their precursors, and techniques, which alter the strength of the protein binding in plasma.
